PubMed · 13529928
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
E J ROSS, G W THORN. 1957-12-15. [Progress in endocrinology].. https://pubmed.ncbi.nlm.nih.gov/13529928/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
This article highlights key historical developments in the understanding of parathyroid function and disease, a story that involves many clinical investigators and classic scientific debate. The current medical community is certainly indebted to the innate curiosity and perseverance of these historical figures.
Inhibin research began in 1923 with the concept of gonadal feedback regulation of pituitary function. A nonsteroidal substance, capable of inhibiting pituitary cell activity was identified in aqueous testicular extracts and named inhibin in 1932. Another 50 years of research was required before inhibin was purified and cloned in 1985, and inhibin's physiology was not revealed until advances in assay technology allowed analysis of circulating levels in animals and humans. Thus, after 80 years of research, a historical retrospective reveals that many advances were required to achieve our present understanding, and yet there is still a long way to go to reach the original objectives of using inhibin, or compounds based on its structure, to regulate fertility pharmaceutically. Nevertheless, this perspective points out important lessons learned during this journey that are applicable to other areas of endocrinology or are opportunities for future research.
Despite multimodality treatment for thyroid cancer, including surgical resection, radioiodine therapy, thyrotropin (TSH)-suppressive thyroxine treatment, and chemotherapy/radiotherapy, survival rates have not improved over the last decades. Therefore, development and evaluation of novel treatment strategies, including gene therapy, are urgently needed. A variety of gene therapy approaches have been evaluated for the treatment of follicular cell-derived and medullary thyroid cancer, including corrective gene therapy (p53 restoration, expression of a dominant negative RET mutant), cytoreductive gene therapy (suicide gene/prodrug strategy herpes simplex virus-thymidine kinase [HSV-tk]/ganciclovir, antiangiogenic therapy with endostatin) and immunomodulatory gene therapy (expression of interleukin (IL)-2 and IL-12). Furthermore, cloning of the sodium iodide symporter (NIS) gene has paved the way for the development of a novel cytoreductive gene therapy strategy based on NIS gene transfer followed by the application of radioiodine therapy ((131)I). NIS gene delivery into medullary and follicular cell-derived thyroid cancer cells has been shown to be capable of establishing or restoring radioiodine accumulation and might therefore represent an effective therapy for medullary and dedifferentiated thyroid tumors that lack iodide accumulating activity. The data summarized in this review article clearly demonstrate that the currently available strategies represent potentially curative novel therapeutic approaches for future gene therapy of thyroid cancer. The combination of different therapeutic genes has been demonstrated to be very useful to enhance therapeutic efficacy and seems to have a promising role at least as part of a multimodality approach for advanced thyroid cancer.